Eurand’s EUR-1073 has been granted orphan drug designation for the treatment of ulcerative colitis in pediatric patients. Orphan drug status is granted to promote the development of drugs for diseases that affect fewer than 200,000 patients. Upon approval, these products have seven years of market exclusivity in the U.S. “We are pleased with the FDA’s decision, and we believe EUR-1073 has the potential to address key unmet medical needs of pediatric patients with ulcerative...